2-ethyl-6-hydroxyhexanoic acid | 86476-36-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: 2-ethyl-6-hydroxyhexanoic acid
• CAS: 86476-36-0
• 化学式: C₈H₁₆O₃
• 分子量: 160.213
• InChiKey: VGKURASSSAVYQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-ethyl-6-hydroxyhexanoic acid 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成 (R)-6-Benzyloxymethoxy-2-ethyl-hexan-1-ol
  参考文献：
  名称：

  Total synthesis of myxovirescin B

  摘要：

  DOI：

  10.1021/jo00298a016
• 作为产物：
  描述：

  2-乙基己烷-1,6-二醇 反应 3.0h， 以19%的产率得到5-ethyl-6-hydroxy-hexanoic acid
  参考文献：
  名称：

  通过电化学再生的氢氧化镍氢氧化物氧化醇。羟基类固醇的选择性氧化

  摘要：

  伯醇，α，ω-二醇和仲醇很容易分别通过在氢氧化镍镍电极上电化学再生的氧化镍氢氧化物进行多相氧化而分别转化为羧酸，二羧酸或酮。与过氧化镍和铬酸氧化的结果进行了讨论。氧化速率随着醇的空间位阻的增加而降低，从而允许羟基甾族化合物中3位的选择性氧化。

  DOI：

  10.1016/0040-4020(82)80110-5

文献信息

• Nitric oxide enhancing diuretic compounds, compositions and methods of use
  申请人：Garvey S. David

  公开号：US20060189603A1

  公开（公告）日：2006-08-24

  The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.

  该发明描述了包含至少一种增强一氧化氮利尿化合物或其药用盐的新型组合物和试剂盒，以及可选地，至少一种增强一氧化氮化合物和/或至少一种治疗剂的试剂盒。该发明还提供了以下方法：(a)治疗由过多水分和/或电解贮留引起的症状；(b)治疗心血管疾病；(c)治疗肾血管疾病；(d)治疗糖尿病；(e)治疗由氧化应激引起的疾病；(f)治疗内皮功能障碍；(g)治疗由内皮功能障碍引起的疾病；(h)治疗肝硬化；(j)治疗子痫前期；(k)治疗骨质疏松症；(l)治疗肾病；(m)治疗外周血管疾病；(n)治疗门静脉高压；(o)治疗中枢神经系统疾病；(p)治疗代谢综合征；(q)治疗性功能障碍；以及(r)高脂血症。增强一氧化氮利尿化合物包括至少一种增强一氧化氮基团，通过碳、氧和/或氮等一个或多个位点与利尿化合物连接，连接通过不能水解的键或基团。
• Polyoxazolines with Inert Terminating Groups, Polyoxazolines Prepared from Protected Initiating Groups and Related Compounds
  申请人：Bentley Michael David

  公开号：US20110123453A1

  公开（公告）日：2011-05-26

  The present disclosure provides novel functional polyoxazoline derivatives prepared by terminating polyoxazoline polymerization with inert chemical groups. In addition, the present disclosure demonstrates the synthesis of novel electrophilic initiators with protected functional groups capable of initiating oxazoline polymerization and capable of surviving the conditions of polymerization. These initiators are used to synthesize the above inert-terminal polyoxazoline derivatives as well as other poly-oxazolines with active terminal groups. Furthermore, the present disclosure provides for polyoxazoline-lipid conjugates and liposomal compositions prepared using such polyoxazoline-lipid conjugates. Methods of using the foregoing to prepare conjugates with target molecules are also disclosed.

  本公开提供了通过使用惰性化学基团终止聚合反应制备的新型功能性聚氧氮杂环衍生物。此外，本公开还展示了合成具有受保护功能基团的新型亲电引发剂的方法，这些引发剂能够引发氧氮杂环聚合反应并能够在聚合反应条件下存活。这些引发剂用于合成上述惰性末端聚氧氮杂环衍生物以及其他具有活性末端基团的聚氧氮杂环。此外，本公开还提供了聚氧氮杂环-脂质共轭物和使用这种聚氧氮杂环-脂质共轭物制备的脂质体组合物。还公开了使用上述方法制备与目标分子结合物的方法。
• Surfactant compounds and uses thereof
  申请人：——

  公开号：US20040234556A1

  公开（公告）日：2004-11-25

  A pharmaceutical aerosol formulation comprising a particulate medicament, one or more fluorocarbon or hydrogen-containing fluorocarbon propellants and a compound of the general formula (I) or a salt or solvate thereof, wherein A represents a straight chain C 1-16 alkylene substituted by n groups of formula B; n represents an integer 1 to 3; and B independently represents C 1-4 fluoroalkylC 0-6 alkylene-, C 1-4 fluoroalkylC 0-6 alkylene-O—, or C 1-4 alkylC 0-6 alkylene-O— wherein at least one substituent of formula B contains at least one fluorine atom and each C 1-4 fluoroalkyl- moiety contains one or more fluorine atoms but not more than 3 consecutive perfluorinated carbon atoms. The invention also extends to uses of compounds of formula (I) and certain novel compounds within the definition of formula (I). 1

  一种制药气雾剂配方，包括颗粒状药物、一种或多种氟碳或含氢氟碳喷射剂和通式（I）的化合物或其盐或溶剂物，其中A代表被n个B式基团取代的直链C1-16烷基；n代表整数1至3；B独立地表示C1-4氟烷基C0-6烷基、C1-4氟烷基C0-6烷基-O-，或C1-4烷基C0-6烷基-O-，其中式B的至少一个取代基含有至少一个氟原子，每个C1-4氟烷基基团含有一个或多个氟原子，但不超过3个连续的全氟碳原子。本发明还涉及使用式（I）化合物和某些新颖的符合式（I）定义的化合物。
• NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：GARVEY David S.

  公开号：US20080255101A1

  公开（公告）日：2008-10-16

  The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.

  这项发明描述了新颖的组合物和试剂盒，包括至少一种增强一氧化氮利尿化合物或其药学上可接受的盐，并且可选地，还包括至少一种增强一氧化氮化合物和/或至少一种治疗剂。该发明还提供了以下方法：(a)治疗由过度水和/或电解质潴留引起的疾病；(b)治疗心血管疾病；(c)治疗肾血管疾病；(d)治疗糖尿病；(e)治疗由氧化应激引起的疾病；(f)治疗内皮功能障碍；(g)治疗由内皮功能障碍引起的疾病；(h)治疗肝硬化；(j)治疗先兆子痫；(k)治疗骨质疏松症；(l)治疗肾病；(m)治疗外周血管疾病；(n)治疗门静脉高压；(o)治疗中枢神经系统疾病；(p)治疗代谢综合征；(q)治疗性功能障碍；以及(r)治疗高脂血症。增强一氧化氮利尿化合物包括至少一个增强一氧化氮基团，通过碳、氧和/或氮等一个或多个位点连接到利尿化合物上，通过无法水解的键或基团连接。
• POLYVINYL ACETAL COMPOSITION, LAMINATE, AND USE THEREOF
  申请人：Asanuma Yoshiaki

  公开号：US20120202070A1

  公开（公告）日：2012-08-09

  It is an object of the invention to provide a plasticized polyvinyl acetal composition that is suitably used for an intermediate film of a laminated glass and other applications, specifically, the polyvinyl acetal composition being characterized in that in cases when a layer that is composed of the polyvinyl acetal composition and another resin layer such as a resin layer of a polycarbonate, a poly(meth)acrylic acid ester, or a styrene thermoplastic elastomer are laminated, the plasticizer does not migrate from the polyvinyl acetal layer. The present invention relates to a polyvinyl acetal composition including 100 parts by mass of a polyvinyl acetal and 0.5 to 100 parts by mass of an ester plasticizer or ether plasticizer that is amorphous or has a melting point of 30° C. or less, and has a hydroxyl value of 15 to 450 mgKOH/g.

  本发明的目的是提供一种塑化的聚乙烯醇醛组合物，适用于夹层玻璃和其他应用的中间膜，具体而言，该聚乙烯醇醛组合物的特点在于，在由聚乙烯醇醛组合物和另一种树脂层（如聚碳酸酯、聚（甲基）丙烯酸酯或苯乙烯热塑性弹性体层的树脂层）组成的层层压合时，塑化剂不会从聚乙烯醇醛层中迁移。本发明涉及一种聚乙烯醇醛组合物，包括100份质量份的聚乙烯醇醛和0.5至100份质量份的酯类塑化剂或醚类塑化剂，其为非晶态或具有30°C或更低的熔点，并具有15至450mgKOH/g的羟值。